These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
249 related items for PubMed ID: 24981850
1. Public spending for illegal drug and alcohol treatment in hospitals: an EU cross-country comparison. Lievens D, Vander Laenen F, Christiaens J. Subst Abuse Treat Prev Policy; 2014 Jun 30; 9():26. PubMed ID: 24981850 [Abstract] [Full Text] [Related]
5. [Public expenditure caused by the consumption of illicit drugs in Germany]. Mostardt S, Flöter S, Neumann A, Wasem J, Pfeiffer-Gerschel T. Gesundheitswesen; 2010 Dec 30; 72(12):886-94. PubMed ID: 20066613 [Abstract] [Full Text] [Related]
8. The costs of alcohol, illegal drugs, and tobacco in Canada, 2002. Rehm J, Gnam W, Popova S, Baliunas D, Brochu S, Fischer B, Patra J, Sarnocinska-Hart A, Taylor B. J Stud Alcohol Drugs; 2007 Nov 30; 68(6):886-95. PubMed ID: 17960307 [Abstract] [Full Text] [Related]
9. Cost of disorders of the brain in Europe 2010. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jönsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen HC, Stovner LJ, Vallat JM, Van den Bergh P, van Os J, Vos P, Xu W, Wittchen HU, Jönsson B, Olesen J, CDBE2010Study Group. Eur Neuropsychopharmacol; 2011 Oct 30; 21(10):718-79. PubMed ID: 21924589 [Abstract] [Full Text] [Related]
10. Hong Kong domestic health spending: financial years 1989/90 to 2008/09. Tin KY, Tsoi PK, Lee YH, Tsui EL, Lam DW, Chui AW, Lo SV. Hong Kong Med J; 2012 Aug 30; 18(4 Suppl 4):1-23. PubMed ID: 22947491 [Abstract] [Full Text] [Related]
12. Spending on substance abuse treatment: how much is enough? Meara E, Frank RG. Addiction; 2005 Sep 30; 100(9):1240-8. PubMed ID: 16128713 [Abstract] [Full Text] [Related]
15. The European challenges of funding orphan medicinal products. Szegedi M, Zelei T, Arickx F, Bucsics A, Cohn-Zanchetta E, Fürst J, Kamusheva M, Kawalec P, Petrova G, Slaby J, Stawowczyk E, Vocelka M, Zechmeister-Koss I, Kaló Z, Molnár MJ. Orphanet J Rare Dis; 2018 Nov 06; 13(1):184. PubMed ID: 30396361 [Abstract] [Full Text] [Related]
17. Recent trends in the financing of substance abuse treatment: implications for the future. Dilonardo J, Chalk M, Mark TL, Coffey RM, CSAT/CMHS Spending Estimates Team. Health Serv Res; 2000 Dec 06; 35(5 Pt 3):60-71. PubMed ID: 16148952 [Abstract] [Full Text] [Related]
18. Disease burden and government spending on mental, neurological, and substance use disorders, and self-harm: cross-sectional, ecological study of health system response in the Americas. Vigo DV, Kestel D, Pendakur K, Thornicroft G, Atun R. Lancet Public Health; 2019 Feb 06; 4(2):e89-e96. PubMed ID: 30446416 [Abstract] [Full Text] [Related]
20. National health expenditures: a global analysis. Murray CJ, Govindaraj R, Musgrove P. Bull World Health Organ; 1994 Feb 06; 72(4):623-37. PubMed ID: 7923542 [Abstract] [Full Text] [Related] Page: [Next] [New Search]